Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Neoplasm Metastasis × eribulin × Clear all

Phase

Status

Completed 8 Active not recruiting 3 Terminated 2 Recruiting 2 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Triple Negative Breast Neoplasms 7 Neoplasm Metastasis 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER2-negative Breast Cancer 1 Breast Neoplasms, Male 1 Breast Cancer Organoids 1 Brain Neoplasms 1

Interventions

Fluorouracil 18 Oxaliplatin 15 Capecitabine 15 Leucovorin 13 Irinotecan 11 Gemcitabine 11 Drug Therapy 11 Cetuximab 10 Radiosurgery 9 Cisplatin 9 Bevacizumab 9 Docetaxel 8 Radiotherapy 6 Paclitaxel 6 Neoadjuvant Therapy 6 Everolimus 6 spartalizumab 5 pembrolizumab 5 Trastuzumab 5 Sunitinib 5 S 1 (combination) 5 Cyclophosphamide 5 Chemotherapy, Adjuvant 5 Carboplatin 5 manganese chloride 4 Surgical Procedures, Operative 4 Sorafenib 4 Nivolumab 4 Immunotherapy 4 Immune Checkpoint Inhibitors 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02175446 2016-06-15

GIM11-BERGI

Consorzio Oncotech

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡